Physician profile
Mark D Aldous
NPI 1396754446
$13,325.72
in general payments reported to CMS, 2019-2025
43 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $874 · 2021: $1,936 · 2022: $2,097 · 2023: $2,705 · 2024: $2,001 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,521 · Travel and Lodging: $632 · Education: $41.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,520.76 |
| Travel and Lodging | $632.01 |
| Education | $41.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,562.08 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,535.47 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $1,093.52 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $956.29 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $894.02 | 2022-2024 | Interstim |
| Janssen Biotech, INC. | $730.11 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Alnylam Pharmaceuticals INC. | $591.96 | 2020-2025 | Givlaari |
| Pfizer INC. | $546.53 | 2019-2025 | |
| Amgen INC. | $318.28 | 2020-2023 | Avsola, Amjevita |
| Boston Scientific Corporation | $300.60 | 2023-2025 | General - Biliary Devices, Exalt Model D |
| Genzyme Corporation | $292.73 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $287.57 | 2019-2023 | Rebyota, Cimzia |
| Intercept Pharmaceuticals, INC. | $263.01 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $226.15 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $217.63 | 2022-2025 | Dupixent |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $207.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $204.68 | 2020-2023 | |
| Celgene Corporation | $203.37 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $197.73 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $176.75 | 2019-2024 | Dificid |
| Aimmune Therapeutics, INC. | $167.37 | 2025 | Zenpep |
| Ucb, INC. | $158.18 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $139.20 | 2025 | Voquezna |
| Organon LLC | $123.31 | 2021-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $103.16 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $101.15 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $91.32 | 2021-2022 | |
| Vivus LLC | $74.44 | 2021-2025 | Pancreaze |
| Evoke Pharma, INC. | $73.30 | 2021-2023 | Gimoti |
| Intra-Sana Laboratories | $70.57 | 2021-2022 | |
| Braintree Laboratories, INC. | $63.98 | 2019-2023 | Suflave |
| Daiichi Sankyo INC. | $62.16 | 2021-2022 | |
| Shire North American Group INC | $59.58 | 2019 | |
| Celltrion USA INC. | $41.97 | 2023-2024 | Zymfentra, Yuflyma |
| Fresenius Kabi USA, LLC | $35.39 | 2024 | Idacio |
| Ethicon US, LLC | $33.82 | 2020-2021 | |
| Romark Laboratories, Lc | $20.71 | 2019 | |
| Sandoz INC. | $19.59 | 2024 | Hyrimoz |
| Novo Nordisk INC | $19.17 | 2024 | Wegovy |
| Alfasigma USA, INC. | $17.31 | 2020 | |
| Covidien LP | $16.03 | 2019 | |
| Teleflex LLC | $14.71 | 2024 | Urolift |
| Allergan, INC. | $13.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Aldous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.